Evidence map›Paper›PMID 26392562›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

SCN5A variant that blocks fibroblast growth factor homologous factor regulation causes human arrhythmia.

Hassan Musa, Crystal F Kline, Amy C Sturm, Nathaniel Murphy, Sara Adelman, Chaojian Wang, Haidun Yan, Benjamin L Johnson, Thomas A Csepe, Ahmet Kilic and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. BIOLOGICAL ANTIARRHYTHMICS-SODIUM CHANNEL INTERACTING PROTEINS.Transactions of the American Clinical and Climatological Association · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Differential Modulation of the Voltage-Gated NaFrontiers in molecular biosciences · 2021
    Article
  19. Article
  20. Characterization of an N-terminal NaBMC medical genetics · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Hassan MusaDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH 43210;
Crystal F KlineDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH 43210;
Amy C SturmDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Internal Medicine, Division of Human Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210;
Nathaniel MurphyDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH 43210;
Sara AdelmanDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH 43210;
Chaojian WangDepartment of Medicine and Ion Channel Research Unit, Duke University Medical Center, Durham, NC 27709;
Haidun YanDepartment of Medicine and Ion Channel Research Unit, Duke University Medical Center, Durham, NC 27709;
Benjamin L JohnsonDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH 43210;
Thomas A CsepeDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH 43210;
Ahmet KilicDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210;
Robert S D HigginsDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210;
Paul M L JanssenDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210;
Vadim V FedorovDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH 43210;
Raul WeissDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210;
Christina SalazarDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210;
Thomas J HundDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Biomedical Engineering College of Engineering, The Ohio State University, Columbus, OH 43210.
Geoffrey S PittDepartment of Medicine and Ion Channel Research Unit, Duke University Medical Center, Durham, NC 27709;
Peter J MohlerDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH 43210; Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210; peter.mohler@osumc.edu.
The Ohio State University Wexner Medical Center · USDuke Medical Center · USDuke University · USDuke University Hospital · US

Funding

Calcium regulation and dysregulation of cardiac ion channelsR01HL071165 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI PITT, GEOFFREY S · 2002 to 2017
$5.2M
Integration of structure and signaling in cardiac pacemaker functionR01HL115580 · NHLBI · OHIO STATE UNIVERSITY · PI FEDOROV, VADIM V · 2013 to 2021
$4.2M
Role of spectrin/ankyrin-G complex in myocyte signaling and cardiac excitabilityR01HL083422 · NHLBI · VANDERBILT UNIVERSITY · PI MOHLER, PETER J. · 2006 to 2016
$3.8M
Role of ankyrin-B in human arrhythmiaR01HL084583 · NHLBI · UNIVERSITY OF IOWA · PI MOHLER, PETER J. · 2006 to 2015
$3.4M
Calmodulin regulation of Na+ channels in neurons and cardiomyocytesR01HL122967 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARX, STEVEN O, PITT, GEOFFREY S · 2015 to 2018
$2.1M
EHD proteins in cardiac membrane protein targeting and remodelingR01HL114383 · NHLBI · OHIO STATE UNIVERSITY · PI BOYDEN, PENELOPE ALTMAN, MOHLER, PETER J. · 2013 to 2016
$2.1M
CaMKII-dependent regulation of cardiac excitabilityR01HL114893 · NHLBI · OHIO STATE UNIVERSITY · PI HUND, THOMAS JEFFREY · 2012 to 2016
$1.9M
Structural studies of NaV1.5 and functional implications.R01HL112918 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI PITT, GEOFFREY S · 2013 to 2016
$1.5M
NHLBI NIH HHS HL071165NHLBI NIH HHS HL083422NHLBI NIH HHS HL084583NHLBI NIH HHS HL114383NHLBI NIH HHS HL114893NHLBI NIH HHS R01 HL071165NHLBI NIH HHS R01 HL083422NHLBI NIH HHS R01 HL084583NHLBI NIH HHS R01 HL112918NHLBI NIH HHS R01 HL114383NHLBI NIH HHS R01 HL114893NHLBI NIH HHS R01 HL115580NHLBI NIH HHS R01 HL122967
6 · The paper itself

Abstract

Nav channels are essential for metazoan membrane depolarization, and Nav channel dysfunction is directly linked with epilepsy, ataxia, pain, arrhythmia, myotonia, and irritable bowel syndrome. Human Nav channelopathies are primarily caused by variants that directly affect Nav channel permeability or gating. However, a new class of human Nav channelopathies has emerged based on channel variants that alter regulation by intracellular signaling or cytoskeletal proteins. Fibroblast growth factor homologous factors (FHFs) are a family of intracellular signaling proteins linked with Nav channel regulation in neurons and myocytes. However, to date, there is surprisingly little evidence linking Nav channel gene variants with FHFs and human disease. Here, we provide, to our knowledge, the first evidence that mutations in SCN5A (encodes primary cardiac Nav channel Nav1.5) that alter FHF binding result in human cardiovascular disease. We describe a five*generation kindred with a history of atrial and ventricular arrhythmias, cardiac arrest, and sudden cardiac death. Affected family members harbor a novel SCN5A variant resulting in p.H1849R. p.H1849R is localized in the central binding core on Nav1.5 for FHFs. Consistent with these data, Nav1.5 p.H1849R affected interaction with FHFs. Further, electrophysiological analysis identified Nav1.5 p.H1849R as a gain-of-function for INa by altering steady-state inactivation and slowing the rate of Nav1.5 inactivation. In line with these data and consistent with human cardiac phenotypes, myocytes expressing Nav1.5 p.H1849R displayed prolonged action potential duration and arrhythmogenic afterdepolarizations. Together, these findings identify a previously unexplored mechanism for human Nav channelopathy based on altered Nav1.5 association with FHF proteins.

Indexed as

Mutation, MissenseAction PotentialsAnimalsArrhythmias, CardiacCells, CulturedChannelopathiesFamily HealthFemaleFibroblast Growth FactorsGenetic Predisposition to DiseaseHEK293 CellsHumansImmunoblottingMaleMice, Inbred C57BLMice, TransgenicFGF12 protein, humanFibroblast Growth FactorsNAV1.5 Voltage-Gated Sodium ChannelSCN5A protein, humanatrial fibrillationchannelopathyFHFion channelNav1.5

Identifiers

PMID26392562
PMCPMC4603502
OpenAlexW1913287761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.